“Long-Term Efficacy and Safety of Risankizumab for CsDMARD-IR Patients With Active Psoriatic Arthritis: 196-Week Results From the KEEPsAKE 1 Trial”. SKIN The Journal of Cutaneous Medicine 8, no. 6 (November 18, 2024): s445. Accessed November 7, 2025. https://skin.dermsquared.com/skin/article/view/3082.